Description

Domain Therapeutics is a preclinical biopharmaceutical company focused on the discovery and development of innovative treatments in immuno-oncology. With teams located in France and Canada, Domain operates multiple technologies aimed at validating G Protein-Coupled Receptors (GPCRs) mediating immunosuppression in the tumour microenvironment, at discovering first-in-class or best-in-class therapies, small molecules and antibodies, and at developing them in the clinic to create a pipeline of high-value proprietary programs. Domain Therapeutics NA Inc., located in Montreal (Quebec, Canada), is the subsidiary of Domain Therapeutics. The research site is dedicated to the operation and development of the BRET bioSens-All® technology platform. This technology allows cutting edge characterization of proximal GPCR signaling profiles. bioSens-All® is used for Domain's internal discovery programs and can also be accessible to biopharmaceutical companies through specific research collaborations, HTS campaigns or SAR studies.